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Following publication of the original article [1], the au-
thors reported that the electrophoretic blots of Figs. 1A,
B, 2A, C, E, 3A, C, E, 4A, B, C, D, 5A, B, C, 6B, D, and F
were published in their raw format. The edited versions
of the complete figures are given below and the original
article [1] has been corrected.
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Fig. 1 Metformin inhibits mTORC1 through AMPK. (a) H1299 cells were treated with the indicated concentrations of metformin or phenformin for
24 h. (b) H1299 cells were transfected with control or AMPKα siRNA for 12 h and were then treated with 10 mM metformin for 24 h. (a, b) Data
are representative of two independent experiments. CTL: control
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Fig. 2 Metformin inhibits mTORC1 through ATF4. (a, b) H1299 cells were treated with the indicated concentrations of metformin for 24 h. (c, d)
H1299 cells were treated with 10 mM metformin for the indicated time. The protein levels (a, c) and mRNA levels (b, d) were estimated by
western blot and RT- PCR analysis, respectively. (a-d) Data are representative of two independent experiments. (e, f) H1299 cells were transfected
with control or ATF4 siRNA for 12 h and were then treated with 10 mM metformin for 24 h. (e) Data are representative of three independent
experiments. (f) The p-S6K expression was quantified using ImageJ software and fold change with respect to control after normalization to
respective S6K bands was plotted as histogram. (n = 3; ***P < 0.001; NS, not significant). CTL: control
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Fig. 3 Metformin induces the expression of REDD1 and Sestrin2 in an ATF4-dependent manner. (a, b, e, f) H1299 cells were treated with the
indicated concentrations of metformin or phenformin for 24 h. (c, d) H1299 cells were transfected with control or ATF4 siRNA for 12 h and were
then treated with 10mM metformin for 24 h. The protein levels (a, c, e) and mRNA levels (b, d, f) were estimated by western blot and real-time
PCR analysis, respectively. (a, c, e) The western blot is representative of two independent experiments. (b, d, f) The real-time PCR results for each
sample were analysed according to the 2−ΔΔCt method using β-actin as the internal control. Gene transcription is presented as the fold change
relative to the control sample (n = 3; ***P < 0.001). CTL: control, SESN1: Sestrin1, SESN2: Sestrin2, SESN3: Sestrin3
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Fig. 4 AMPK and ATF4 do not affect each other’s expression under metformin treatment. (a–d) H1299 cells were transfected with control, AMPKα,
ATF4, REDD1, or Sestrin2 siRNA for 12 h and then treated with 10mM metformin for 24 h. The indicated protein levels were estimated by western
blot analysis. The blot is representative of two independent experiments. CTL: control, SESN2: Sestrin2
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Fig. 5 Metformin-induced REDD1 and Sestrin2 expression is involved in mTORC1 inhibition by metformin. (a-e) H1299 cells were transfected with
control, REDD1, Sestrin2, or REDD1/Sestrein2 siRNA for 12 h and then treated with 10 mM metformin for 24 h. (a, b, c) The indicated protein levels
were estimated by western blot analysis. (upper panels; a, b, c) The blot is representative of three independent experiments. (bottom panels; a, b,
c) The p-S6K protein expression was quantified using ImageJ software and fold change with respect to control after normalization to respective
S6K protein bands was plotted as histogram (n = 3; ***P < 0.001; ns, not significant). (d, e) The indicated mRNA levels were estimated by real-time
PCR analysis. The real-time PCR results for each sample were analysed according to the 2−ΔΔCt method using β-actin as the internal control. Gene
transcription is presented as the fold change relative to the control sample (n = 3; *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant). CTL:
control, SESN2: Sestrin2
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Fig. 6 (See legend on next page.)
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Fig. 6 Lapatinib enhances cell sensitivity to metformin, and knockdown of REDD1 and Sestrin2 decreases cell sensitivity to metformin and
lapatinib. (a) H1299 cells were treated with the indicated concentrations of metformin for 24 h. (b) H1299 cells were treated with 10 mM
metformin and/or 10 μM lapatinib for 12 h. (c) H1299 cells were treated with 10 mM metformin and/or 10 μM lapatinib for 24 h. (d, f) H1299 cells
were transfected with control, ATF4 or REDD1/Sestrin2 siRNA for 12 h followed by treatment with 10 mM metformin and 10 μM lapatinib for 12 h.
(e, g) H1299 cells were transfected with control, ATF4, or REDD1/Sestrin2 siRNA for 12 h followed by treatment with 10 mM metformin and 10 μM
lapatinib for 24 h. (a. c, e, g) Cell viability was measured by MTT assay. The data are presented as the mean percentage of control ± SD relative to
the control (n = 3; *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significantly different). (b, d, f) The indicated protein levels were estimated by western
blot analysis. Data are representative of three independent experiments. CTL: control, Lapa: Lapatinib, Met: metformin, SESN2: Sestrin2
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